Letrozole
- Generic Name
- Letrozole
- Brand Names
- Femara, Kisqali Femara Co-pack
- Drug Type
- Small Molecule
- Chemical Formula
- C17H11N5
- CAS Number
- 112809-51-5
- Unique Ingredient Identifier
- 7LKK855W8I
- Background
Letrozole, or CGS 20267, is an oral non-steroidal type II aromatase inhibitor first described in the literature in 1990. It is a third generation aromatase inhibitor like exemestane and anastrozole, meaning it does not significantly affect cortisol, aldosterone, and thyroxine.
Letrozole was granted FDA approval on 25 July 1997.
- Indication
Letrozole is indicated to treat postmenopausal women with hormone receptor (HR) positive early breast cancer, postmenopausal women with early breast cancer who have periviously been treated with tamoxifen, and postmenopausal women with HR+ or unknown advanced breast cancer. Letrozole, given with ribociclib, is indicated to treat pre, peri, and postmenopausal...
- Associated Conditions
- Advanced Breast Cancer, Anovulatory cycle, Epithelial Ovarian Cancer, HR+, HER2-, Advanced Breast Cancer, Stage I Breast Cancer, Metastatic HR + HER2 - breast cancer
- Associated Therapies
- -
Letrozole Versus Clomifene Citrate for Ovulation Induction
- Conditions
- Interventions
- First Posted Date
- 2007-05-24
- Last Posted Date
- 2016-10-28
- Lead Sponsor
- University of Nottingham
- Target Recruit Count
- 159
- Registration Number
- NCT00478504
- Locations
- 🇬🇧
Royal Derby Hospital, Derby, Derbyshire, United Kingdom
Randomized Phase II Study of Preoperative Letrozole (Femara) in Combination With Avastin in Hormone Receptor Positive Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2007-04-18
- Last Posted Date
- 2021-03-16
- Lead Sponsor
- Yale University
- Target Recruit Count
- 5
- Registration Number
- NCT00461773
- Locations
- 🇺🇸
Yale University, Yale Cancer Center, New Haven, Connecticut, United States
Genetic Testing or Clinical Assessment in Determining the Need for Chemotherapy in Women With Breast Cancer That Involves No More Than 3 Lymph Nodes
- Conditions
- Interventions
- First Posted Date
- 2007-02-12
- Last Posted Date
- 2022-11-17
- Target Recruit Count
- 6600
- Registration Number
- NCT00433589
- Locations
- 🇳🇱
Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands
Letrozole In Combination With Lapatinib In Neoadjuvant Treatment Of Early Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2007-01-17
- Last Posted Date
- 2016-05-12
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 92
- Registration Number
- NCT00422903
- Locations
- 🇪🇸
GSK Investigational Site, Badalona, Spain
Vitamin D Deficiency, Muscle Pain, Joint Pain, and Joint Stiffness in Postmenopausal Women Receiving Letrozole For Stage I-III Breast Cancer
- Conditions
- Interventions
- Drug: letrozoleDietary Supplement: calcium carbonateOther: laboratory biomarker analysisDietary Supplement: calcium citrateDietary Supplement: calcium glucarateDrug: calcium gluconateDietary Supplement: cholecalciferolProcedure: assessment of therapy complicationsProcedure: musculoskeletal complications management/prevention
- First Posted Date
- 2006-12-28
- Last Posted Date
- 2017-07-11
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 100
- Registration Number
- NCT00416715
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
Letrozole Versus Observation in Patients With Newly Diagnosed Uterine Leiomyosarcoma
- First Posted Date
- 2006-12-21
- Last Posted Date
- 2018-11-20
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 9
- Registration Number
- NCT00414076
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
HOBOE: A Phase 3 Study of Adjuvant Triptorelin and Tamoxifen, Letrozole, or Letrozole and Zoledronic Acid in Premenopausal Patients With Breast Cancer.
- Conditions
- Interventions
- First Posted Date
- 2006-12-15
- Last Posted Date
- 2023-03-24
- Lead Sponsor
- National Cancer Institute, Naples
- Target Recruit Count
- 1294
- Registration Number
- NCT00412022
- Locations
- 🇮🇹
Istituto Nazionale per la ricerca Sul Cancro, Genova, Italy
🇮🇹Ospedale Santa Chiara, Trento, Italy
🇮🇹Ospedale Unico della Versilia, Lucca, Italy
Chemotherapy and Hormone Therapy as First-Line Therapy in Treating Postmenopausal Women With Metastatic or Locally Advanced Breast Cancer
- Conditions
- First Posted Date
- 2006-11-23
- Last Posted Date
- 2012-06-01
- Lead Sponsor
- Technical University of Munich
- Registration Number
- NCT00403182
- Locations
- 🇩🇪
Kreiskrankenhaus, Ebersberg, Germany
🇩🇪Frauenklinik Universitaet Giessen, Giessen, Germany
🇩🇪Munich Oncologic Practice at Elisenhof, Munich, Germany
Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer
- First Posted Date
- 2006-09-28
- Last Posted Date
- 2024-03-22
- Lead Sponsor
- NSABP Foundation Inc
- Target Recruit Count
- 3966
- Registration Number
- NCT00382070
- Locations
- 🇺🇸
USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States
🇺🇸Mason District Hospital, Havana, Illinois, United States
🇺🇸St. Agnes Hospital Cancer Center, Baltimore, Maryland, United States
Efficacy and Safety of Letrozole vs. Letrozole Plus Zoledronic Acid as Endocrine Therapy Before Surgery in Postmenopausal Patients With Breast Cancer
- First Posted Date
- 2006-09-13
- Last Posted Date
- 2017-06-26
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 168
- Registration Number
- NCT00375752
- Locations
- 🇩🇪
Novartis Investigative Site, Ulm, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.